drugset / Trial / NCT00830102
Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients
RandomizedCrossoverDouble-blindTreatment
Summary
The primary purpose was to evaluate the efficacy of SKP FlutiForm HFA MDI compared to placebo or fluticasone and formoterol administered concurrently or alone in asthma patients.
Timeline
- Start
- 2004-10
- Primary completion
- 2005-01
- Completion
- 2005-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fluticasone propionate | Other / unclassified | 100 ug | Inhaled |
| Comparator | Fluticasone propionate | Other / unclassified | 250 ug | Inhaled |
| Comparator | Formoterol | Other / unclassified | 10 ug | Inhaled |
| Comparator | Formoterol | Other / unclassified | 12 ug | Inhaled |